Pelthos Therapeutics Inc. Common Stock PTHS 深 沪
交易中 09-10 10:19:32 美东时间
31.7096
+0.140
+0.44%
华盛通- 最 高31.7096
- 今 开31.57
- 成交量 633股
- 最 低 31.7096
- 昨 收 31.57
- 总市值 9646.38万
- 52周最高 54.29
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.50
- 委 比 -92.31%
- 总股本 304.21万
- 历史最高 60.00
- 量 比 0.33
- 振 幅 0.00%
- 历史最低 4.50
- 每 手 1
- 风险率 6.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
Pelthos Therapeutics Inc. announced that CEO Scott Plesha and CFO Frank Knuettel II will participate in two upcoming conferences: the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8-10, 2025, and the Investor Summit Group Q3 Virtual Conference on September 16-17, 2025. Pelthos is a biopharmaceutical company focused on commercializing innovative therapeutic products, with its lead product, ZELSUVMI™, approv...
09-08 12:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pelthos Therapeutics (AMEX:PTHS) stock increased by 25.9% to $28.27 du...
09-04 01:06
Pelthos Therapeutics Presents at Wells Fargo Conference
Pelthos Therapeutics ( ($PTHS) ) just unveiled an announcement. On September 2,...
09-03 20:58
Oppenheimer Initiates Coverage On Pelthos Therapeutics with Outperform Rating, Announces Price Target of $50
Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces Price Target of $50.
09-02 20:20
Pelthos Therapeutics GAAP EPS of -$5.38
Pelthos Therapeutics press release (NYSE:PTHS): Q2 GAAP EPS of -$5.38. Cash $59.17M More on Pelthos Therapeutics Seeking Alpha’s Quant Rating on Pelthos Therapeutics Historical earnings data for Pel...
08-19 00:50
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
Pelthos Therapeutics Inc. has shared its financial results for legacy operations as of June 30, 2025, marking the final standalone report before its merger with Channel Therapeutics. Key highlights include the completion of the merger and a $50.1 million private placement to support the launch of ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum. The company has hired 50 territory sales managers and built out its opera...
08-18 12:00
Pelthos Therapeutics Q2 EPS $(5.38) Beats $(6.26) Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.38) per share which beat the analyst consensus estimate of $(6.26) by 14.06 percent. This is a 75.24 percent decrease over losses of $(3.07) per share
08-14 05:41
美股牛股 | 稀土矿商MP飙升逾50%！五角大楼将成其最大股东；KLG隔夜涨超30%
稀土矿商MP飙升逾50%！五角大楼将成其最大股东；KLG隔夜涨超30%，获费列罗31亿美元收购>>
07-11 18:21
Ligand Pharm's Partner Pelthos Therapeutics Commercially Launches ZELSUVMI Topical Gel 10.3%, FDA-Approved At-Home Treatment For Molluscum Contagiosum
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only
07-10 20:09
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
Ligand Pharmaceuticals announced that its partner Pelthos Therapeutics has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, earning Ligand a $5 million milestone payment. Ligand now owns 56% of Pelthos post-merger and is entitled to a 13% royalty on ZELSUVMI sales and up to an additional $5 million in milestones. ZELSUVMI, developed using Ligand's NITRICIL™ technology, is the first topical prescription medic...
07-10 12:00
